Vanguard Asset Management’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.17M Buy
126,094
+11,074
+10% +$646K ﹤0.01% 852
2026
Q2
$6.69M Buy
115,020
+5,777
+5% +$314K ﹤0.01% 908
2026
Q1
$6.35M Buy
+109,243
New +$5.93M 0.01% 829

Other funds holding PCVX

Vanguard Asset Management's PCVX Position: Q3 2026 in Review

Vanguard Asset Management increased its Vaxcyte (PCVX) stake by 9.6% in Q3 2026, buying an estimated $646K and bringing the position to 126,094 shares worth $7.17M. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Vanguard Asset Management first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • Vanguard Asset Management held 126,094 shares of Vaxcyte worth $7.17M as of Q3 2026.
  • Vanguard Asset Management bought 11,074 Vaxcyte shares in Q3 2026, an estimated $646K.
  • Vaxcyte made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #852 holding.
  • Vanguard Asset Management first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
  • 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.